Core Insights - The Hang Seng Innovation Drug ETF (159316) has seen a 1.47% increase as of July 9, 2025, with a trading volume of 3.09 billion yuan, indicating active market participation [1] - As of July 8, the ETF's latest scale reached 498 million yuan, with a total of 386 million shares, both marking new highs since its inception [1] - Recent net inflow into the ETF amounted to 28.55 million yuan, with a total of 79.19 million yuan attracted over the past five trading days [1] - The National Medical Products Administration (NMPA) has announced measures to optimize the lifecycle regulation supporting the innovation of high-end medical devices, which is expected to benefit high-end medical equipment and in vitro diagnostics (IVD) significantly [1] - The Hang Seng Innovation Drug ETF closely tracks the Hang Seng Innovation Drug Index, which reflects the performance of Hong Kong-listed companies involved in the research, development, and production of innovative drugs [1][2] Industry Summary - The Hang Seng Innovation Drug ETF (159316) is currently the only ETF product tracking the Hang Seng Innovation Drug Index, providing investors with a unique opportunity to capitalize on the current innovation drug investment landscape in Hong Kong [2]